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Abstract: B cell neoplasms co-opt the molecular machinery of normal B cells for their survival. 
Technological advances in cancer genomics has significantly contributed to uncovering the root 
cause of aggressive lymphomas, revealing a previously unknown link between TLR signaling 
and B cell neoplasm. Recurrent oncogenic mutations in MYD88 have been found in 39% of the 
activated B cell-like subtype of diffuse large B cell lymphoma (ABC DLBCL). Interestingly, 
29% of ABC DLBCL have a single amino acid substitution of proline for the leucine at posi-
tion 265 (L265P), and the exact same variant has also been identified in a number of lymphoid 
malignancies. The MYD88 L265P variant was recently identified in 90% of Wadenstrom’s 
macroglobulinemia patients. These recent developments warrant the need for novel diagnostic 
tools as well as targeted therapeutics. In this review, we discuss the physiological functions 
of MYD88 and focus on its role in B cell lymphomas, evaluating the potential for targeting 
oncogenic MYD88 in lymphoma.
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Introduction
From one of the earliest detailed descriptions of lymphoma cases by Hodgkin in 1832, it 
was already evident that this group of cancer is very diverse.1 Such heterogeneity poses 
significant challenges to the effective diagnosis, management and study of lymphomas. 
Following decades of progress in the understanding of the biology of white blood 
cells and ‘the hallmarks of cancers’, we now know lymphomas are characterized by 
neoplastic transformation of lymphocytes at various differentiation stages.2,3 Given 
the diversity in the subsets of lymphocytes and the numerous differentiation stages, 
from the common hematopoietic stem cell precursor to distinct differentiated states, 
the diagnosis, treatment and study of lymphoid neoplasms remain central clinical 
challenges.
The current classification of lymphomas resulted from a major collaborative effort 
by the World Health Organization (WHO) synthesizing information about the immu-
nophenotype, genetic features, and clinical characteristics, along with the traditionally 
used cell/tissue morphology to define specific clinically relevant diseases.4 The WHO 
classification broadly segregates neoplasms based on myeloid and lymphoid lineages, 
followed by sub-categorization into functional or cell differentiation stages of the 
normal counterpart of each neoplasm. The 2008 WHO classification lists more than 
one hundred tumors of the hematopoietic and lymphoid tissues, for most of which the 
underlying causes are still unknown.
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Lymphoid neoplasms are the sixth most common cancer 
worldwide, with close to one million new cases expected to 
be diagnosed each year.5 The most common hematopoietic 
tumors diagnosed are non-Hodgkin lymphoma, leukemia, 
multiple myeloma and Hodgkin’s lymphoma. B lymphocyte 
neoplasms account for about 90% of all newly diagnosed 
cases, among which diffuse large B cell lymphoma (DLBCL) 
and follicular lymphoma are the most prevalent.6
B cell lymphomas are thought to co-opt the molecular 
features of normal B cells for their survival, such that the phe-
notype of malignant B cells mirror the state of differentiation 
from which they originate. During B cell development, 
B cells express a number of DNA-modifying enzymes 
such as recombinase-activating gene (RAG1 and RAG2), 
which primarily serves to increase diversity of antibodies 
in the repertoire.7 A side consequence of such enzymes is 
the generation of chromosomal translocations, which may 
contribute to malignancy.7 Another stage of differentiation 
at which B cells are very susceptible to genomic alterations 
is the transient germinal centre (GC) stage.8 During the GC 
stage, B cells express activation-induced cytidine deaminase 
(AID), a DNA-modifying enzyme that is required for somatic 
hypermutation and class switching of antibodies.9 The off-
target effect of AID may also contribute to the oncogenic load 
in B cells.10–12 Thus, GC B cells may give rise to several types 
of lymphoma, including the diffuse-large B cell lymphoma, 
follicular lymphoma and Burkitt’s lymphoma.13
Diffuse large B cell lymphoma (DLBCL) is one of the 
most common forms of lymphoma, accounting for 30%–40% 
of all newly diagnosed cases.6 DLBCL is also currently one 
of the least curable lymphoma, with about 50%  success 
using a combination of chemotherapy and rituximab.14 
With the advent of genome-wide gene expression profiling, 
DLBCL has been subdivided into three molecular subtypes.15 
The  activated B cell (ABC), germinal-center B cell (GCB) 
and the primary mediastinal B cell lymphoma (PMBL) 
 subtypes are histologically indistinguishable, but differ in the 
expression of hundreds of signature genes.15 The subdivision 
of DLBCL holds promise for better diagnosis and improved 
treatment regimes, even though the use of gene expression 
profiling is yet to be translated into clinical practice.
Among the three subtypes of DLBCL, the ABC subtype 
has been associated with the lowest success rates following 
standard treatment regimes.14 Interestingly, gene expression 
profiling and drug inhibition studies revealed that the ABC 
subtype has a striking dependence on signaling pathways 
activating the transcription factor NFκB.15,16 The constitu-
tive NFκB activation in ABC DLBCL could contribute to 
the poor response following chemotherapy as the targets 
of this family of transcription factors prevent apoptosis.17 
These findings emphasized the need for the development of 
therapeutics targeting NFκB signaling for the treatment of 
aggressive lymphomas.
A recent wave of progress in cancer genomics triggered 
by next-generation sequencing technologies have signifi-
cantly contributed to uncovering the root cause of the high 
NFκB activity in ABC DLBCL (Figure 1). The survival 
of this aggressive lymphoma subtype relies on signaling 
from the antigen receptor to the NFκB transcription fac-
tors, with CARD11, BCL10 and MALT1 being essential 
components of the signaling apparatus.16 In approximately 
10% of patients, gain-of-function mutations in the CARD11 
oncogene have been found to activate NFκB and prolong cell 
survival.18 In addition, about 20% of ABC lymphomas have 
mutations in CD79A or CD79B, which are rare or absent in 
GCB and other lymphoma subtypes.19 Loss of function muta-
tions resulting in the inactivation of A20, a negative regulator 
of NFκB signaling, has been found to occur in 25% of ABC 
lymphomas.20–22 Crippling the activity of A20 increases the 
activity of NFκB signaling in malignant B cells.23
More recently, high-throughput RNA resequencing 
of DLBCL has identified recurrent oncogenic mutations 
in MYD88 in 39% of ABC DLBCL tumors.24,25 These 
findings established a previously unknown link between 
TLR signaling and B cell lymphoma. Interestingly, 29% 
of ABC DLBCL have a single amino acid substitution of 
proline for the leucine at position 265 (L265P) in the TIR 
domain.24,25 The MYD88 L265P variant has also been identi-
fied in a number of lymphoid malignancies (Table 1). The 
MYD88 L265P variant was recently identified in about 90% 
of Wadenstrom’s macroglobulinemia patients, revealing 
a central pathogenic feature of this tumor.26 These recent 
developments warrant the need for novel diagnostic tools 
as well as targeted therapeutics. In this review, we discuss 
the physiological functions of MYD88 and focus on its role 
in B cell lymphomas, evaluating the potential for targeting 
oncogenic MYD88 in lymphoma.
Physiological function of MYD88
MYD88 was originally identified as a myeloid differentiation 
primary response gene in hematopoiesis.27 Following treat-
ment of myeloid cell precursors with interleukin 6 (IL6), 
the levels of MYD88 transcript was found to increase as 
cells terminally differentiated.27 MYD88 is essential for 
the mammalian innate immune response. Individuals with 
MYD88 deficiency suffer life threatening recurrent pyogenic 
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bacterial infection by Streptococcus pneumonia, Staphylococ-
cus aureus and Pseudomonas aeruginosa,  suggesting that 
MYD88 plays a crucial role in the innate immune response 
in the Toll/IL1 receptor pathways.28,29 Furthermore, mice lack-
ing MYD88 also show impaired Toll receptor and IL1/IL18 
responses in addition to defects in T cell proliferation and Th1 
response.30 These defects result from the inability of signals 
to be transmitted from ligand activated receptors to the NFκB 
and JNK pathways.30 Thus, MYD88 plays a central role as an 
adaptor molecule to transducing signals from receptors such 
as Toll-like receptor/IL-1 receptor to transcription factors.
A homolog of MYD88 in Drosophila, known as Tube, 
was initially described as an adaptor protein for Toll-Dorsal 
signaling and is essential for establishing dorsal-ventral 
polarity during embryogenesis.31 Moreover, MYD88 deficient 
drosophila flies have crippled defense against fungal and 
microbial infections, and mammalian models of MYD88 
deficiency have drastically poor defense against a plethora 
of pathogens.32,33 Given the crucial role of MYD88 in the 
immune system of a wide range of organisms, it is not sur-
prising that this adaptor molecule has been evolutionarily 
conserved.
Toll like receptors (TLR) play essential roles as the danger 
sensing molecular detector in an innate immune response.34 
TLRs are type I transmembrane protein that share homology 
with the interleukin-1 receptor. In total, ten different members 
of TLRs are differentially expressed amongst different immune 
cell subtypes, each responding to a different type of stimulus.35 
Figure 1 Oncogenic mutations targeting the NFκB pathway. Oncogenic mutations frequently target the MYD88, CD79, and CARD11 (part of the CMB complex) in 
aggressive lymphomas. Consequences of these mutations include disruption to normal cellular signal transduction events such as protein phosphorylation, ubiquitylation or 
deubiquitylation, which converge onto aberrant NFκB activity, a hallmark of lymphomas with L265P MYD88. Specific inhibitors targeting (1) MYD88, (2) IRAK4, (3) Toll-like 
receptor (TLR), (4) NFkB, and BTK are currently in clinical trials. 
Note: Targeting these molecular pathways may provide effective treatment to patients.
Abbreviations: AP-1, activator protein 1; BCR, B cell receptor; BTK, Bruton tyrosine kinase; CBM, CARD11-BCL10-MALT1 complex; CD79, cluster of differentiation 79; 
Fyn, Src family protein tyrosine kinase Fyn; Lyn, Src family protein tyrosine kinase Lyn; IkBα, inhibitor of NFkB alpha; IKK, inhibitor of kB alpha kinase; IRAK1, interleukin 1 
receptor associated kinase 1; IRAK4, interleukin 1 receptor associated kinase 4; MAPK, mitogen activated protein kinase; MYD88, myeloid differentiation factor 88; NFkB, 
nuclear factor kappa-light-chain-enhancer of activated B cells; Syk, spleen tyrosine kinase; TAB1, TGF beta activated kinase 1 binding protein 1; TAB2, TGF beta activated 
kinase 1 binding protein 2; TAK1, TGF beta activated kinase 1; TGF, transforming growth factor; TLR, Toll like receptor; TNF, tumor necrosis factor; TRAF6, TNF receptor 
associated factor 6.
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Different combinations of adaptor molecules create distinct 
signaling platforms, which recruit additional signal transduction 
molecules giving rise to a range of responses governed by differ-
ential gene expression.34 Signaling by all TLRs, with the excep-
tion of TLR3, requires MYD88 as an adaptor molecule.34
During bacterial infections, macrophages form an 
important first line of defense as part of the innate immune 
response. Macrophages can be potently activated by lipopoly-
saccharide (LPS), a major component of the Gram-negative 
bacteria outer membrane, through the stimulation of Toll-
like receptor 4.34 Stimulated macrophages produce various 
cytokines such as tumor necrosis factor alpha (TNFα), IL1, 
IL6/10 and inflammatory effector chemokines.36 By using 
MYD88 deficient mice, Akira and colleagues elucidated 
the role of MYD88 in macrophage activation in response to 
endotoxin.37 MYD88 deficient mice fail to produce proin-
flammatory cytokines such as TNFα, IL1 and IL6 after LPS 
challenge.37 Cultured macrophages from MYD88 deficient 
mice show no increase in mRNA level in proinflammatory 
cytokines upon LPS treatment, highlighting the importance 
of MYD88 in response to bacterial infection.37
MYD88 signaling in B lymphocytes
B lymphocytes have also been shown to respond to LPS 
through their Toll-like receptors, resulting in proliferation 
and production of cytokines such as IL1, IL6, IL8 and 
TNFα.38 LPS activated B cells also enhance their antigen 
presentation capacity through increased MHC II expression 
as well as secretion of large amounts of LPS-neutralizing 
antibodies, such that in response to LPS MYD88 deficient 
B cells have impaired MHC II upregulation as well as poor 
proliferation and antibody secretion.37,38 The response fol-
lowing recognition of bacterial DNA by TLR9 through a 
specific CpG motif,39,40 requires MYD88 as B cells without 
the adaptor molecule fail to proliferate in response to CpG 
DNA.41 MYD88 plays central role in the response of B cells 
following various stimuli through the Toll-like receptors.
MYD88 acts as a key adaptor protein linking danger 
signals from Toll-like receptors to transcription factors, 
which regulate cellular gene expression. Molecular studies 
revealed that MYD88 forms a protein complex with interleu-
kin 1 receptor (IL1R) and interleukin 1 receptor-associated 
kinase (IRAK), a serine threonine protein kinase, in the 
presence of IL1.42,43 MYD88 is first recruited to the cyto-
plasmic tail of IL1R or TLRs following their engagement 
via homophilic TIR interactions and the formation of a 
homodimer.44 IRAK4 is then recruited to the site of activa-
tion through the interactions between the death domains, 
resulting in the activation of IRAK4 and the phosphorylation 
of the downstream protein kinase IRAK1.42 Subsequently, 
phosphorylated IRAK1 associates with TRAF6 in the 
cytoplasm and leads to the activation of the NFκB and 
MAPK pathways (Figure 1).34 Through a poorly defined 
mechanism, following IRAK1 mediated phosphorylation, 
TRAF6 disassociates from the receptor complex and forms a 
cytoplasmic complex that consists of TRAF6/TAB2/TAK1.34 
Activated TAK1 phosphorylates both the β subunit of IKK 
and MAPK kinase 6.34 Activated IKKβ in turn phosphorylate 
IκBα, leading to its ubiquitylation and proteasomal degrada-
tion, allowing the NFκB dimer to translocate to the nucleus 
and activate gene transcription that regulates cell activation, 
proliferation and immune responses.34
Oncogenic MYD88 in lymphoma
MYD88 forms an important link in the activation and 
proliferation of B cells under a number of different extra-
Table 1 Frequency of somatic MYD88 mutations in B cell 
neoplasm
Disease MYD88  
mutation
Frequency  
(case/sample)
Reference
ABC DLBCL L265P 29%# 24
ABC DLBCL Others 10%# 24
BL Other 5%# 24
CBCL L265P 69% (11/16) 70
CLL L265P 2.9% (9/310) 71
CLL M232T 2.2% (2/91) 72
CLL P258L 1.1% (1/91) 72
CLL L265P 6.6% (6/91) 72
GCB DLBCL Other 6%# 24
IgM MGUS L265P 10% (2/21) 73
LPL L265P 91% (49/54) 73
MALT L265P 9%# 24
MALT L265P 3.8% (2/53) 74
MALT 27 bp  
deletion*
1.9% (1/53) 74
MZL L265P 6.5% (3/46) 75
PCNSL L265P 36% (5/14) 76
PCNSL L103L 7% (1/14) 76
PCNSL Q143E 7% (1/14) 76
PCNSL L265P 38% (11/29) 77
SMZL L265P 13% (6/46) 78
SMZL L265P 5.1% (6/117) 79
Notes: #Percentage in published text inconsistent with calculated percentage from 
biopsy number; *deletion occurred between gene sequence 1039–1065, resulting in 
amino acid deletion between v286-T294.
Abbreviations: ABC-DLBCL, activated B-cell like diffuse large B-cell lymphoma; 
BL, Burkitt’s lymphoma; CBCL, cutaneous diffuse large B-cell lymphoma (leg type); 
CLL, chronic lymphocytic leukemia; GCB-DLBCL, germinal center B-cell like diffuse 
large B cell lymphoma; IgM MGUS, IgM monoclonal gammopathy of undetermined 
significance; LPL, lymphoplasmacytic lymphoma (Waldenström’s Macroglobulinemia 
or non-IgM LPL); MALT, gastric mucosa-associated lymphoid tissue lymphoma; 
MZL, marginal zone lymphoma; PCNSL, primary central nervous system lymphoma; 
SMZL, splenic marginal zone lymphoma.
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cellular stimuli. It is thus not surprising that defects in 
this critical signal relay molecule may result in pathol-
ogy in B cell activation and proliferation that result 
from aberrant NFκB and MAPK activity.34 ABC DLBCL 
has characteristically constitutive NFκB activity that 
enhances the proliferation and survival of the affected B 
cell populations. Sequencing studies of DLBCL samples 
and RNA interference screens using human lymphoma 
cell lines revealed MYD88 mutations are present in 39% 
of samples.24 MYD88 was found to be required for the 
survival of the cell lines through constitutive activation 
of NFκB signaling.24
The MYD88 L265P variant was recently identified in 
about 90% of Wadenstrom’s macroglobulinemia patients, 
constituting a significant clinical feature for this disease.26 
Albeit at lower frequencies, L265P MYD88 was also found 
in cases of chronic lymphocytic leukemia, splenic marginal 
zone lymphoma, primary central nervous system lymphoma 
and gastric mucosa-associated lymphoid tissue lymphoma 
(Table 1). The L265P mutation affects the MYD88 TIR 
domain, which is responsible for recruiting the protein to 
the cytoplasmic tail of TLRs to form an active complex, 
which subsequently activates the kinases IRAK1 and 
IRAK4 to signal downstream.45 A hyperphosphorylated 
slow migrating isoform of IRAK1 associates strongly with 
the L265P mutant MYD88 but not wild type MYD88 sug-
gesting a gain-of-function activity in the L265P mutant.24 
The MYD88 L265P mutation was also found to be a potent 
driver of high NFκB activity, which is characteristic of 
ABC DLBCL.24
Interestingly, in addition to enhancing NFκB signaling, 
MYD88 L265P seems to increase JAK-STAT signaling and 
interferon production, indicating the potential involvement 
of a niche microenvironment important for tumor survival.24 
STAT3 signaling induced by cytokines such as IL6 could 
provide additional survival signals sustaining lymphoma 
survival, given that transgenic mice expressing supra-
physiological amounts of IL6 develop a range of lymphoid 
malignancies, including DLBCL.46 Thus, IL6 and IL10 
production potentially form an important autocrine feed-
back loop that activates JAK-STAT signaling to enhance the 
survival of ABC DLBCL.24,47 Interestingly, overexpression 
of the L265P MYD88 variant has recently been associated 
with reduced disease free survival and increased disease 
recurrence in DLBCL patients.48 These recent developments 
highlight MYD88 as a specific target for therapeutic interven-
tion, and warrants the development of inhibitors targeting the 
MYD88-NFκB signaling axis.
Targeting oncogenic MYD88
Aberrant NFκB activation has been associated with poor 
clinical outcomes in many lymphomas and leukemia. Thus, 
effective therapeutic agents targeting the NFκB pathway may 
allow the achievement of desirable outcome for a subset of 
patients. Given the large proportion of lymphoid neoplasms 
with aberrant TLR signaling, targeting the MYD88 pathway is 
becoming an attractive option for clinicians and researchers.
Direct inhibition of MYD88
A critical event in MYD88 mediated signaling is the homodi-
merization of MYD88 through its TIR and DD domains.49 
The dimerization of MYD88 promotes its recruitment to the 
plasma membrane and docking with the TIR domain of the 
cytoplasmic tails of TLRs or IL1R, as well as the recruitment 
of IRAK4 and IRAK1 through the interaction between their 
DD domains.43,50 Given signal transduction through MYD88 
requires its homodimerization and lymphoma associated 
MYD88 mutations occur exclusively in the TIR domain, one 
appealing option would be to ‘switch off’ this signaling relay 
event so that MYD88 homodimerization and downstream 
signaling is inhibited.
TIR-TIR interaction in MYD88 is achieved by distinct 
conserved residues in a structure known as the BB-loop that 
lies between the second β-strand and the second α-helix.51 
The interference of this interaction was successfully achieved 
by the use of heptapeptides mimicking BB-loop by Sette and 
colleagues.51 When this dimerization is inhibited, significant 
reduction in NFκB activity is achieved in cells stimulated 
with IL1 or TLR agonists but not poly(I:C), a TLR3 ago-
nist, suggesting this component selectively inhibits MYD88 
dependent signaling.51 The same group also identified a novel 
synthetic compound, ST2825, which mimics the heptapeptide 
in the BB-loop of MYD88 and this compound is currently 
undergoing preclinical evaluations.52
Alternative options to specifically target MYD88-
MYD88 and MYD88-receptor interactions through the 
TIR domain would be to use small molecule inhibitors such 
as Hydrocinnamoyl-L-valyl pyrrolidine (compound 4a).53 
This particular low molecular weight compound is cell 
membrane permeable and specifically disrupts MYD88-
receptor interactions by inhibiting TIR domain interactions. 
Another peptide Pepinh-MYD developed by InvivoGen, 
which carries a 26 amino acid MYD88 homodimerization 
motif, could also potentially be used to treat lymphoma 
patients with L265P MYD88. However, these potential 
MDY88-specific therapeutic options are yet to be trialed 
in large clinical cohorts.
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Targeting IRAK4, downstream  
of receptor-MYD88 signaling
Interleukin receptor-associated kinases (IRAKs) are a key 
component of the signal transduction pathways downstream 
of IL1 receptor or TLRs, and are required for the  activation 
of NFκB and MAPKs in response to the activation of these 
receptors.34 In particular, IRAK4 serves as the “master 
IRAK” by having the ability to phosphorylate and activate 
other IRAKs. The MYD88 L265P mutation result in a 
constitutively activated signaling complex, which includes 
IRAK4 and phosphorylated IRAK1.24 Since ABC DLBCL 
lines depend on kinase activity of IRAK4, but not IRAK1, 
inhibiting IRAK4 kinase activity could be a potent way of 
‘tuning down’ aberrant NFκB and MAPK pathways activated 
by MYD88 mutations.
The activation of IRAK4 is regulated by the autophos-
phorylation of three serine and threonine sites in its activa-
tion loop.54 The autophosphorylation of these key activating 
residues confer a conformation change to allow the ATP-
binding site to become activated.54 The kinase activity of 
IRAK4 is thus often targeted by small molecular inhibitors 
that bind to the ATP-binding site. In ABC DLBCL cell lines 
carrying the MYD88 L265P mutation, disrupting IRAK4 sig-
naling by a small molecule inhibitor led to the decreased 
phosphorylation of IRAK1, IκBα, NFκB p65 and STAT3 
(unpublished data). Two small molecule IRAK4 inhibitors 
(ND-2110 and ND-2158) developed by Nimbus Discovery 
are highly selective against more than 300 kinases and seem 
promising, although these drugs are still in the preclinical 
stage.
Targeting the two ends-inhibiting TLRs 
and the NFκB signaling
It has long been speculated that cognate antigen stimula-
tion might contribute to lymphomagenesis.55 Since MYD88 
physiologically serves as an adaptor molecule for TLR 
sensing pathogens, it is an attractive idea that lymphomas 
with MYD88 mutations need external or internal signals 
from TLRs for their survival. However, it remains unclear 
whether oncogenic mutant MYD88 proteins require upstream 
signaling from ligand-activated receptors for enhancing its 
activity. But, in the potential scenario where ligand-TLR 
engagement would be required for oncogenic MYD88 activa-
tion, inhibiting TLR signaling upstream of MYD88 can be a 
potential therapeutic target for treating B cell malignancies 
carrying MYD88 mutations. TLR antagonists which are 
currently under preclinical and clinical evaluation could be 
potentially used to inhibit receptor signaling.56
An alternative point at which signaling from oncogenic 
MYD88 could be interrupted would be through direct inhibi-
tion of NFκB activity. In recent years, more than 800 drugs 
that inhibit NFκB signaling have been developed, and their 
 mechanisms of action have been characterized.57,58 For instance 
drugs such as emetine, bithionol, narasin and  lestaurtinib 
inhibit NFκB signaling via inhibition of IkBα phosphoryla-
tion, a critical step required for activation of NFκB, while 
drugs such as bortezomib and Carfilzomib inhibit NFκB 
activity by dampening proteosomal degradation of IkBα.59 
Even though a number of NFκB inhibitors are FDA-approved 
for use in particular cancer types, inhibition of this particular 
family of transcription factors would be accompanied by a 
number of undesired side-effects. NFκB is known to have 
a critical role across many cellular processes including cell 
proliferation, apoptosis, immune responses to infection, and 
inflammation, such that the beneficial effects and potential 
collateral damage must be carefully examined.60
Combination therapy
Lenalidomide (Revlimid®, Celgene Corporation, Summit, NJ, 
USA), a derivative of thalidomide, is an immunomodulatory 
drug and currently used as a treatment of multiple myeloma 
and myelodysplastic syndromes.61,62 Although the mechanism 
of action still remains unclear, clinical trials showed lenali-
domide is effective against most lymphomas. ABC DLBCL 
had a significantly higher response rate to the thalidomide 
analog compared to GC DLBCL, indicating that one of its 
actions is a suppressive effect on the NFκB pathway.63
A recent study from Staudt et al found synergistic effects 
between lenalidomide and a BTK inhibitor, ibrutinib.64 They 
found that lenalidomide was partially toxic to ABC DLBCL 
lines by inhibiting NFκB, JAK and MYD88 signaling as well 
as augmenting IFN beta signature.64 IFN beta production and 
upregulation of IFN beta-responsive genes is characteristic 
of ABC DLBCL harboring MY88 mutations, although its 
pathological roles are still unclear since IFN beta is known 
to induce cell cycle arrest and apoptosis paradoxically.65 IFN 
beta production is induced by IRF7 in a positive-feedback 
manner and IRF4/SPIB transcription factor network represses 
IFN beta production by downregulating IRF7.66 Ibrutinib 
cooperates with lenalidomide to kill ABC DLBCL lines, 
presumably due to inducing IFN beta pathway by changing 
the balance between IRF7 and IRF4/SPIB.64
Another potential strategy of combination therapy would 
be to block IRAK4 signaling and BTK signaling in synergy. 
This strategy is consistent with the observation that survival 
of ABC DLBCL cell lines require a signal through both the 
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TLR and the BCR as knocking down CD79 molecule of 
the BCR signaling compartment synergistically kills ABL-
DLBCL cell lines with MYD88 knockdown.24 Therefore syn-
ergistic killing of lymphoid neoplasms with L265P MYD88 
using a combination of IRAK inhibitor and BTK inhibitor 
strongly indicate that most potent therapy should target both 
the TLR and BCR pathways simultaneously.
Concluding remarks
Recent discoveries have uncovered the involvement of 
L265P MYD88 in a number of diseases, but the effects 
of this oncogenic variant remain unclear. Future research 
would help elucidate the effects of deregulated MYD88 
on cellular signaling pathways, the activity of transcription 
factors, and gene expression changes. However, from the 
initial biochemical characterization of oncogenic MYD88, it 
is apparent that several key signaling pathways are disrupted 
such that effective therapeutic strategies would involve multi-
pronged approaches with combination of specific agents 
 targeting biochemically distinct pathways simultaneously. Such 
therapeutic regimes remain to be evaluated in large cohorts of 
patients, and a factor central to evaluation of the effectiveness 
of such treatment regimes would be the appropriate selection 
of patients. Recently, a number of diagnostic tools have been 
developed to specifically detect the presence of the L265P 
MYD88 variant in clinical samples.67–69 With the refinement 
of these diagnostic methods and the development of targeted 
therapeutics, clinicians would, in the near future, be in a better 
position to provide treatment options to previously incurable 
diseases.
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